Vontobel Holding Ltd. Makes New $69,000 Investment in enGene Holdings Inc. (NASDAQ:ENGN)

Vontobel Holding Ltd. acquired a new position in enGene Holdings Inc. (NASDAQ:ENGN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,417 shares of the company’s stock, valued at approximately $69,000.

A number of other institutional investors have also recently made changes to their positions in the company. Franklin Resources Inc. grew its holdings in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after buying an additional 389,918 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after buying an additional 619,100 shares during the last quarter. Finally, Wolverine Asset Management LLC purchased a new stake in shares of enGene during the third quarter valued at approximately $37,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ENGN shares. UBS Group cut shares of enGene from a “buy” rating to a “neutral” rating and cut their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th. Raymond James initiated coverage on shares of enGene in a report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target on the stock. Piper Sandler initiated coverage on shares of enGene in a report on Tuesday. They issued an “overweight” rating and a $26.00 target price on the stock. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Finally, HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They issued a “buy” rating and a $25.00 target price on the stock. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $25.89.

enGene Stock Up 2.0 %

ENGN opened at $6.24 on Friday. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene Holdings Inc. has a 1-year low of $4.42 and a 1-year high of $18.40. The company has a market capitalization of $276.07 million, a PE ratio of -10.76 and a beta of -0.65. The firm’s 50 day simple moving average is $6.76 and its two-hundred day simple moving average is $7.20.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, equities analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.